About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGPhase 1NCT04678648

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have ...

Lead sponsor: RasCal Therapeutics, Inc.•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Bonnie Wettersten, MS

CONTACT

(847) 644-9818 clinicaltrials@rascaltherapeutics.com

Sponsors

Lead Sponsor

RasCal Therapeutics, Inc.

RSC-1255 is an orally bioavailable, small-molecule direct pan-mutant and wild-type RAS inhibitor. RSC-101 is a Phase 1a/1b, open-label, multi-center, non-randomized, Dose Escalation and Dose Expansion study in participants with advanced solid tumor malignancies. Study enrollment is approximately 134 participants. All participants receive oral RSC-1255, twice daily as monotherapy. Following Phase 1a (Dose Escalation) to identify the Maximum Tolerated Dose and Recommended Dose for use in Phase 1b, additional participants are enrolled in the Phase 1b (Dose Expansion) to further characterize the safety, pharmacology, and the clinical efficacy of RSC-1255 as monotherapy and in combination with the autophagy inhibitor hydroxychloroquine (HCQ).

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:
•* Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition
•* Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit
•* Malignancy has progressed on standard therapy
•2. Has evaluable or measurable tumor(s) in dose-escalation by standard radiological and/or laboratory assessments as applicable to their malignancy.
•3. Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG).
•4. Is age ≥ 18 years.
•5. Has either tissue agnostic tumors and documented RAS mutations or with glioblastoma with or without mutation in RAS

Exclusion Criteria

•1. Participants receiving cancer therapy at the time of enrollment.
•2. Any clinically significant disease or condition affecting a major organ system.
•3. Significant cardiovascular disease or electrocardiogram (ECG) abnormalities.
•4. Known Gilbert's disease.
•5. Has had a previous (within 2 years) or has a current malignancy other than the target cancer.
•6. Intermittent hypokalemia
•7. Grade 1 or higher nausea, vomiting, diarrhea at baseline due to underlying disease

Related studies

RECRUITINGPhase 3

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137 · Non Small Cell Lung Cancer

RECRUITINGPhase 3

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

RECRUITINGPhase 2

A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer

NCT07444437 · Non-Small Cell Lung Cancer

RECRUITINGPhase 2

A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer

NCT07489716 · Non-Small Cell Lung Cancer

RECRUITINGPhase 2

A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities

NCT07308106 · Non-small Lung Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 18, 2026Terms

Trial snapshot

StatusRECRUITING

PhasePHASE1

Enrollment134

Start dateMar 2021

Last updatedMar 18, 2026

Condition

Advanced Malignant Solid Neoplasm RAS Mutation Lung Cancer Colon Cancer Glioblastoma+1 more

Locations shown

University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology

Los Angeles, California

Sarah Cannon, SCRI Oncology Partners - Health One

Denver, Colorado

Sarah Cannon, SCRI Oncology Partners

Nashville, Tennessee

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 18, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions